GRI Bio Stock Price, News & Analysis

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor Closing Bell Series. CEO Marc Hertz, PhD will present on May 28, 2025, at 4:00 PM ET.

The event will include a corporate overview, business outlook, and a live Q&A session with investors. The presentation will be webcast live on the company's website and will remain accessible for 90 days after the event.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in A.G.P.'s Annual Healthcare Company Showcase. CEO Marc Hertz, PhD will engage in a fireside chat on Wednesday, May 21, 2025, at 2:40 PM ET. The virtual event will be accessible via webcast through the Events page in the Investors section of GRI Bio's website.

GRI Bio (NASDAQ: GRI) reported its Q1 2025 financial results and provided updates on its Phase 2a trial of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The company highlighted positive interim 2-week safety and biomarker results from the first 12 patients, showing an anti-fibrotic effect trend. Patient enrollment for the 6-week interim analysis (n=24) is complete, with over two-thirds of overall trial enrollment finished. The company recently closed a $5.0 million public offering and reported a Q1 2025 net loss of $3.0 million. With current cash of $3.3 million plus the new offering, GRI Bio expects to fund operations through Q3 2025. Key upcoming milestones include 6-week interim results in Q2 2025 and topline results in Q3 2025.

GRI Bio (NASDAQ: GRI) reported encouraging interim biomarker results from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) found that the first 12 patients showed a positive trend towards anti-fibrotic effects, with no safety concerns. The company has completed enrollment for the 6-week interim analysis (N=24) and achieved over 70% total enrollment. The Phase 2a study is a randomized, double-blind trial evaluating GRI-0621 4.5mg versus placebo in approximately 36 IPF patients. Key timelines include interim data expected in Q2 2025 and topline results in Q3 2025. Initial 2-week safety results showed GRI-0621 to be well-tolerated, with no hyperlipidemia observed and lipid levels remaining within normal ranges.

GRI Bio (NASDAQ: GRI) has announced significant progress in its Phase 2a clinical trial of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The study has completed enrollment for the 6-week interim analysis with 24 out of 36 planned patients now enrolled. The randomized, double-blind study administers GRI-0621 4.5mg or placebo orally once daily for 12 weeks. Previously reported 2-week safety results from the first 12 patients showed the drug to be safe and well-tolerated, with no hyperlipidemia observed. The company expects to report interim biomarker data in Q2 2025 and topline results in Q3 2025. The study's primary endpoint focuses on safety and tolerability, with secondary endpoints including changes in serum biomarkers and pharmacokinetics assessment.

GRI Bio (NASDAQ: GRI) announced that its abstract has been selected for a poster discussion session at the 2025 American Thoracic Society (ATS) International Conference in San Francisco, CA, from May 18-21, 2025. The presentation, titled 'Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis,' will be delivered by CEO Marc Hertz, PhD.

The presentation is scheduled for Wednesday, May 21, 2025, from 8:15-10:15 AM PT in Room 2022/2024 at the Moscone Center. It will be part of the session 'D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR' and will be displayed on Poster Board Number 810.

GRI Bio (NASDAQ: GRI) has successfully closed its previously announced public offering, raising $5.0 million in gross proceeds. The offering included 1,388,888 shares of common stock along with three series of warrants (E-1, E-2, and E-3) at a combined price of $3.60 per share.

The warrants, exercisable immediately at $3.20 per share, have varying expiration periods: Series E-1 expires in 5 years, Series E-2 in 18 months, and Series E-3 in 9 months. If fully exercised, these warrants could generate additional gross proceeds of $13.3 million.

H.C. Wainwright & Co. served as the exclusive placement agent. The biotechnology company, focused on developing Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases, plans to use the net proceeds for product candidate development, working capital, and general corporate purposes.

GRI Bio (NASDAQ: GRI) has announced the pricing of a $5.0 million public offering consisting of 1,388,888 shares of common stock (or equivalents) and three series of warrants. The offering is priced at $3.60 per share with accompanying Series E-1, E-2, and E-3 warrants.

The warrants have an exercise price of $3.20 per share, with varying expiration periods: Series E-1 expires in 5 years, Series E-2 in 18 months, and Series E-3 in 9 months. If fully exercised, the warrants could generate additional gross proceeds of $13.3 million.

The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around April 2, 2025. The company plans to use the proceeds for product candidate development, working capital, and general corporate purposes.

GRI Bio (NASDAQ: GRI) has reported encouraging interim safety results from its ongoing Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The Independent Data Monitoring Committee recommended continuing the study as planned, with no safety concerns identified in the first 12 patients evaluated.

The study evaluates GRI-0621, a RAR-βɣ dual agonist administered at 4.5mg orally once daily. Initial results show the drug is safe and well-tolerated, with no hyperlipidemia observed in the assessed patients. The Phase 2a trial will enroll approximately 36 subjects in a 2:1 ratio (GRI-0621 vs. placebo) for a 12-week treatment period.

The study's primary endpoint focuses on safety and tolerability, with secondary endpoints including changes in serum biomarkers and pharmacodynamic activity. Interim biomarker data is expected in Q2 2025, with topline results anticipated in Q3 2025.